PT-141 Peptide

Multiple Phase 2/3 clinical trials established PT-141/bremelanotide efficacy:

• RECONNECT trials: Statistically significant improvement in desire and reduction in distress in premenopausal women with HSDD (p<0.001)
• Male studies: 67% of men with erectile dysfunction achieved erections sufficient for intercourse (vs 20% placebo)
• Onset: Effects begin within 30-60 minutes of administration
• Key advantage: Works through central arousal pathways, effective regardless of vascular status

PT-141 melanocortin activation also modulates appetite circuits. MC4R in the PVN is a key integration point for leptin/ghrelin signaling. Research shows PT-141 reduces food intake in animal models through anorexigenic signaling, connecting sexual function and metabolic regulation through the same melanocortin pathway.

PT-141 activates MC4R in the paraventricular nucleus, the same receptor implicated in appetite regulation. Loss-of-function MC4R mutations are the most common monogenic cause of obesity in humans. Research shows PT-141 administration reduces food intake in animal models through anorexigenic POMC/CART neuron activation. This connects the melanocortin system to both reproductive and metabolic physiology.

Interestingly, the MC4R agonist setmelanotide (Imcivree) was FDA-approved for genetic obesity caused by POMC, PCSK1, or LEPR deficiency — validating the melanocortin pathway as a viable metabolic target and supporting further research with MC4R agonists like PT-141.

Beyond sexual function, melanocortin agonists including PT-141 have shown cytoprotective effects in ischemia-reperfusion models. MC4R activation triggers anti-inflammatory cascades (reduced TNF-α, IL-6, IL-1β) and anti-apoptotic signaling via PI3K/Akt pathway activation. Preclinical studies demonstrated improved organ survival and reduced mortality in hemorrhagic shock models treated with melanocortin agonists.

The melanocortin receptor family (MC1R-MC5R) mediates diverse physiological functions. PT-141 binding affinities: MC4R > MC3R >> MC1R > MC5R. This selectivity profile is crucial — MC4R mediates sexual arousal and appetite regulation, MC3R modulates energy homeostasis, while minimal MC1R activity avoids the skin darkening seen with Melanotan II. The cyclic structure and D-Phe7 substitution are responsible for this selectivity.

Comparison with other melanocortin agonists: setmelanotide (MC4R-selective, approved for genetic obesity), MTII (non-selective, causes tanning), alpha-MSH (endogenous, short half-life). PT-141 offers the best balance of MC4R potency with manageable selectivity for research applications.

The RECONNECT program comprised two pivotal Phase 3, randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) evaluating subcutaneous bremelanotide (1.75 mg) in premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). These trials enrolled a combined total of approximately 1,247 women over 24 weeks of treatment, with participants self-administering the compound at least 45 minutes before anticipated sexual activity.

Key findings from the RECONNECT program included:

• Desire: Bremelanotide-treated participants demonstrated a statistically significant increase in the Female Sexual Function Index (FSFI) desire domain score compared to placebo (mean change from baseline: +0.5 vs. +0.2, p < 0.001 in the pooled analysis).
• Distress: The Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score (distress related to low sexual desire) decreased significantly in the bremelanotide group compared to placebo (mean change: −1.0 vs. −0.6, p < 0.001).
• Satisfying sexual events (SSEs): A modest but statistically significant increase in SSEs was observed, though the primary endpoints were desire and distress, not frequency of events.
• Tolerability: The most commonly reported adverse events were nausea (reported in approximately 40% of the bremelanotide group vs. 1% placebo), flushing, headache, and transient injection site reactions. Nausea was typically mild to moderate and decreased with continued use.
• Blood pressure: Transient increases in systolic and diastolic blood pressure (mean ~3 mmHg) were observed within 2–3 hours of administration, returning to baseline within 12 hours.

The RECONNECT data formed the basis of the FDA's June 2019 approval of bremelanotide (Vyleesi®) for premenopausal HSDD. The approval was notable as it validated a melanocortin-mediated, centrally acting mechanism for sexual desire modulation, distinct from any previously approved pharmacological approach.

The earliest clinical evidence for the erectogenic properties of melanocortin receptor agonists emerged from controlled studies of both Melanotan II and PT-141 in male subjects with erectile dysfunction (ED). In a landmark double-blind, placebo-controlled crossover study, Wessells and colleagues (1998) administered the melanocortin agonist subcutaneously to men with psychogenic ED and monitored penile tumescence using RigiScan. Subjects receiving active compound demonstrated clinically meaningful erectile responses — defined as rigidity at the penile tip exceeding 80% for at least 10 minutes — significantly more often than those receiving placebo.

Subsequent Phase 2 research specifically evaluated PT-141 administered intranasally in men with ED (Diamond et al., 2004). Key results included:

• A dose-dependent increase in erectile response at 7 mg and 20 mg intranasal doses compared to placebo.
• RigiScan data showed significant improvement in both tip and base rigidity, with responses occurring within 30 minutes of administration.
• Erectile responses were observed even in a subset of patients who had not responded to sildenafil, supporting the hypothesis of a CNS-mediated mechanism independent of PDE5 pathway modulation.
• Common adverse events included nausea and flushing; no clinically significant changes in blood pressure were reported at the doses studied.

These findings provided important preclinical and early clinical evidence that the melanocortin system represents a pharmacologically tractable target for sexual function research operating through a fundamentally different mechanism than established peripheral vasodilators.

The melanocortin system is a central integrator of energy homeostasis, and PT-141's activity at MC3R and MC4R positions it as a relevant probe for appetite and feeding behavior research. MC4R agonists in general have been associated with reduced food intake in preclinical models, and loss-of-function mutations in MC4R represent the most common monogenic cause of severe obesity in humans, affecting an estimated 2–5% of severely obese individuals.

In animal models, administration of melanocortin agonists targeting MC4R consistently produces anorectic effects. Fan et al. (1997) demonstrated that intracerebroventricular injection of the MC4R agonist MTII (the parent compound of PT-141) suppressed food intake in both fasted and ad libitum-fed rodents, an effect completely blocked by co-administration of the MC3R/MC4R antagonist SHU9119. Subsequent research by Kask et al. (1998) confirmed that these effects were mediated through hypothalamic circuits in the arcuate nucleus and PVN.

Key observations from melanocortin appetite research relevant to PT-141 include:

• MC4R knockout mice develop hyperphagia and obesity, demonstrating the receptor's tonic role in appetite suppression.
• MC3R knockout mice show increased adiposity without increased food intake, suggesting a role in energy partitioning and metabolic efficiency rather than satiety per se.
• Peripheral administration of PT-141 at doses used in sexual function research has been associated with mild nausea in clinical trials, which may partially reflect central melanocortin-mediated modulation of visceral afferent signaling and brainstem emetic circuits.

These findings underscore the broad physiological role of the melanocortin pathway and highlight PT-141 as a research tool for studying the intersection of metabolic and reproductive neuroendocrine circuits.

An emerging area of melanocortin research involves the protective effects of MC receptor agonism in models of hemorrhagic shock, ischemia-reperfusion injury, and systemic inflammation. This line of investigation originated from the observation that alpha-MSH and its analogs possess anti-inflammatory and cytoprotective properties mediated in part through MC3R and MC4R signaling in immune and vascular tissues.

Catania and colleagues have extensively documented that melanocortin peptides modulate NF-κB signaling, inhibit the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, and attenuate neutrophil infiltration in organ injury models. Specifically, PT-141 and related melanocortin agonists have been investigated in rodent models of hemorrhagic shock with the following observations:

• Administration of melanocortin agonists reduced organ damage scores in liver and intestine following controlled hemorrhage and resuscitation.
• Plasma TNF-α and IL-6 levels were significantly attenuated in treated groups compared to vehicle controls.
• Protective effects were associated with preserved microvascular perfusion and reduced leukocyte-endothelial adhesion in intravital microscopy studies.
• The effects were blocked by MC3R/MC4R antagonists, confirming melanocortin receptor dependence.

These findings suggest that the melanocortin system may function as an endogenous anti-inflammatory circuit, and that exogenous agonists like PT-141 could serve as research tools for studying organ-protective mechanisms in shock and ischemia-reperfusion settings. Research in this area remains preclinical.

Understanding PT-141's receptor selectivity profile is essential for interpreting its pharmacological effects and distinguishing it from related melanocortin peptides. The five melanocortin receptors (MC1R–MC5R) have distinct tissue distributions and physiological roles:

• MC1R — Skin melanocytes; mediates pigmentation (melanogenesis). Activation by α-MSH or Melanotan II leads to eumelanin synthesis.
• MC2R — Adrenal cortex; the ACTH receptor. Exclusively activated by ACTH; no significant PT-141 activity.
• MC3R — Hypothalamus, limbic system, peripheral immune cells; involved in energy homeostasis, feeding, and inflammation. PT-141 EC₅₀ ~14 nM.
• MC4R — Hypothalamus (PVN, MPOA), brainstem, spinal cord; mediates sexual function, appetite suppression, autonomic regulation, and cardiovascular reflexes. PT-141 EC₅₀ ~2.9 nM.
• MC5R — Exocrine glands, immune cells; involved in sebaceous gland function and immunomodulation.

Comparative binding and functional data illustrate the pharmacological distinction between PT-141 and its parent compound Melanotan II:

The structural modification that converts Melanotan II to PT-141 — specifically, removal of the N-terminal acetyl group's metabolic pathway and C-terminal amide, producing a free-acid C-terminus — reduces MC1R-mediated melanogenic activity while preserving potent MC3R/MC4R agonism. This selectivity refinement has been instrumental in developing PT-141 as a more targeted melanocortin research tool with a cleaner pharmacological profile for CNS-mediated endpoint studies.